Louwai Muhammed

Louwai Muhammed is a British entrepreneur and investor with a background spanning neuroscience, medicine, and venture capital. He trained as a physician and was ranked first in the UK for entry to London academic medical training, before pivoting into the life sciences investment and startup ecosystem. He won first prize at the MIT $100k Accelerate Technology Entrepreneurship Competition and has since worked across biotech investment and company building, including as part of the BACKED VC team.

Louwai is Co-Founder of CoSyne Therapeutics, a London-based AI drug discovery company focused on glioblastoma multiforme — the most aggressive and treatment-resistant form of primary brain cancer. CoSyne uses a polymathic AI platform combining computational systems biology, genomics, and machine learning to identify molecular vulnerabilities in tumour cells and stratify patients for existing and novel therapies. The company brings together experts in mathematics, biology, chemistry, physics, and AI to build a vertically integrated precision medicine platform.

CoSyne Therapeutics has raised £3.3 million in funding from investors including BACKED VC, Amino Collective, and Phoenix Court. The company is headquartered in London's Soho, with laboratory operations at the Milner Therapeutics Institute in Cambridge, and is focused on advancing its computational stratification approach toward clinical application in one of oncology's most challenging disease areas.